ESP | ENG

OTHER SAD INDUCED BY ANTI-TNF AGENTS (31-12-07)

a) Inflammatory myopathies

First autor
Patients
Age
Gender
Rheumatic disease
Anti-TNF administered
AD triggered
Urata
1
52
F
RA
Infliximab
Polymyositis
May
1
44
F
RA
Etanercept
Dermatomyositis
Flendrie
1
52
F
RA
Lenercept
Dermatomyositis
Musial
1
52
F
RA
Infliximab
Polymyositis

b) Sclerosis/sclerederma

First autor
Patients
Age
Gender
Rheumatic disease
Anti-TNF administered
AD triggered
Ranganathan
1
52
F
RA
Infliximab
Scleredema

c) Autoimmune hepatitis

First autor
Patients
Age
Gender
Rheumatic disease
Anti-TNF administered
AD triggered
Germano
1
53
F
PsA
Infliximab
Autoimmune hepatitis
Marques
1
34
F
UC
Infliximab
Autoimmune hepatitis
Ozorio
1
56
F
AS
Infliximab
Autoimmune hepatitis
Tobon
1
39
F
RA
Infliximab
Autoimmune hepatitis
Tobon
1
52
F
RA
Infliximab
Autoimmune hepatitis
Menghini
1
44
F
CD
Infliximab
Cholestatic hepatitis
Saleem
1
36
F
RA
Infliximab
Autoimmune hepatitis

d) Inflammatory eye diseases

First author
Patients
Age
Gender
Rheumatic disease
Anti-TNF administered
AD triggered
Reddy
1
44
F
AS
Etanercept
Anterior uveitis
Kaipiainen
1
31
F
JIA
Etanercept
Anterior uveitis
Smith
1
46
M
PsA
Etanercept
Uveitis
Smith
1
51
F
RA
Etanercept
Anterior uveitis
Tiliakos
1
58
F
RA
Etanercept
Anterior uveitis
Tiliakos
1
48
F
RA
Etanercept
Scleritis
Smith
1
61
F
RA
Etanercept
Scleritis
Smith
1
56
M
RA
Etanercept
Scleritis
Smith
1
45
F
RA
Etanercept
Scleritis
Caramaschi
1
42
F
RA
Etanercept
Orbital myositis
Taban
1
52
F
AS
Etanercept
Anterior uveitis
Tran
1
45
F
PsA
Infliximab
Optic neuritis
Agarwal
1
65
F
RA
Infliximab
Endogenous endophthalmitis
Di Gangi
1
48
F
RA
Infliximab
Uveitis